

**LungLife AI, Inc.**  
(the "Company" or "LungLife")

**Nodule evaluation using LungLB® projected to be cost-effective in US healthcare system**

*Data strongly support payor coverage of indeterminate lung nodule evaluation using LungLB® in peer-reviewed publication in the Journal of Medical Economics.*

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that further to its announcement on 27 February 2023, the final version of the health economics publication is now available. There have been no changes to the results or conclusions, which show LungLB® is projected to be a cost-effective solution for US insurers covering individuals with indeterminate lung nodules.

The publication can now be accessed here: [Journal of Medical Economics Vol 26](#)

**For further information please contact:**

**LungLife AI, Inc.**  
Paul Pagano, CEO  
David Anderson, CFO

[www.lunglifeai.com](http://www.lunglifeai.com)  
Via Walbrook PR

**Investec Bank plc (Nominated Adviser & Broker)**  
Virginia Bull / Cameron MacRitchie / Lydia Zychowska

**Tel: +44 (0)20 7597 5970**

**Walbrook PR Limited**  
Stephanie Cuthbert / Alice Woodings / Phillip Marriage

**Tel: +44 (0)20 7933 8780 or [LungLifeAI@walbrookpr.com](mailto:LungLifeAI@walbrookpr.com)**  
**Mob: 07980 541 893 / 07407 804 654 / 07867 984 082**

**About LungLife**

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit [www.lunglifeai.com](http://www.lunglifeai.com)

Our Purpose is to be a driving force in the early detection to lung cancer. Our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCBQLLBXXLFBBF